《新股》疫苗公司中慧元通生物科技通過上市聆訊
江蘇中慧元通生物科技近日通過聯交所上市聆訊,將由中信證券及招銀國際擔任聯席保薦人。
聆訊後初步資料顯示,中慧元通成立於2015年,是一家總部位於中國的疫苗生產商,目前擁有四價流感病毒亞單位疫苗「慧爾康欣」及在研凍乾人用狂犬病疫苗兩款核心產品,以及11種在研疫苗項目,涵蓋對疫苗接種有龐大需求的多個疾病領域。
截至今年3月底止首季,該公司錄收入41.3萬元人民幣,按年增長近35%,期內虧損達到8,731.7萬元人民幣,較2024年同期的虧損6,333.1萬元人民幣擴大。
中慧元通曾於2023年6月申請於上交所科創板上市,隨後於同年9月撤回申請,主要考慮到聯交所生物科技板塊內的活躍籌資活動、把握國際市場機遇的未來戰略及上交所科創板的上市時間表的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.